Acute interactions between endothelin and nitric oxide in the control of renal haemodynamics

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 3, 1999, Pages 253-257

  Baylis, Chris ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Afferent resistance; Efferent resistance; Glomerular blood pressure; Glomerular filtration rate; K(f); Renal plasma flow; Renal vascular resistance

Indexed keywords

ENDOTHELIN; NITRIC OXIDE;

BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONFERENCE PAPER; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY TUBULE PRESSURE; KIDNEY VASCULAR RESISTANCE; MEDIATOR RELEASE; RECEPTOR BLOCKING; REGULATORY MECHANISM; VASOCONSTRICTION;

ANIMALS; ENDOTHELIN-1; HUMANS; NITRIC OXIDE; RENAL CIRCULATION; VASOCONSTRICTOR AGENTS;

EID: 0033057585     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03026.x     Document Type: Conference Paper

References (59)

1. 1. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the kidney. Editorial review. Am. J Physiol. 1997; 272: F561-78.
2. 2. Boulanger C, Luscher TF. Release of endothelin from porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 1990; 85: 587-90.
3. 3. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J. Clin. Invest. 1993; 92: 99-104.
4. 4. DeNucci G, Thomas R, D'Orleans Juste P et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl Acad. Sci. USA 1988; 85: 9797-800.
5. B receptor in endothelial cells: Receptor coupling to nitric oxide synthase. J. Biol. Chem. 1994; 269: 21 778-85.
6. 6. Verhaar MC, Strachan FE, Newby DE et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752-6.
7. 7. Goligorsky MS, Tsukahara H, Magazine H, Anderson TT, Malik AB, Bahou WF. Termination of endothelin signaling: Role of nitric oxide. J. Cell Physiol. 1994; 158: 485-94.
8. 8. Kohan DE. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 1997; 29: 2-26.
9. 9. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. J. Clin. Invest. 1989; 83: 336-42.
10. 10. King AJ, Brenner BM, Anderson S. Endothelin: A potent renal and systemic vasoconstrictor peptide. Am. J. Physiol. 1989; 256: F1051-8.
11. 11. Kon V, Yoshioka T, Fogo A, Ichikawa I. Glomerular actions of endothelin in vivo. J. Clin. Invest. 1989; 83: 1762-7.
12. 12. Fretschner M, Edlich K, Gulbins E, Lang RE, Schlottmann K, Steinhausen M. Effects of endothelin on the renal microcirculation of the split hydronephrotic rat kidney. Renal Physiol. Biochem. 1991; 14: 112-27.
13. 13. Bloom I, Bentley F, Wilson M, Garrison R. In vivo effects of endothelin on the renal microcirculation. J. Surg. Res. 1993; 54: 274-80.
14. 14. Loutzenhiser R, Epstein M, Hayashi K, Horton C. Direct visualization of effects of endothelin on the renal microvasculature. Am. J. Physiol. 1990; 258: F61-8.
15. 15. Edwards R, Trizna W, Ohlstein E. Renal microvascular effects of endothelin. Am. J. Physiol 1990; 259: F217-21.
16. 16. Ito S, Juncos LA, Nushiro N, Johnson CS, Carretero OA. Endothelium-derived relaxing factor modulates endothelin action in arterioles. Hypertension 1991; 17: 1052-6.
17. 17. Lanese DM, Yuan BH, McMurtry IF, Conger JD. Comparative sensitivities of isolated rat renal arterioles to endothelin. Am. J. Physiol. 1992; 263: F894-9.
18. 18. Takabatake T, Ise T, Ohta K, Kobayashi K. Effects of endothelin on renal hemodynamics and tubuloglomerular feedback. Am. J. Physiol. 1992; 263: G103-8.
19. 19. Kawabata M, Han W, Ise T, Kobayashi K, Takabatake T. Role of endogenous endothelin and nitric oxide in tubuloglomerular feedback. Kidney Int. 1996; 49: 55; S135-7.
20. A receptor activation. Am. J. Physiol. 1993; 264: R222-6.
21. B receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br. J. Pharmacol. 1994; 111: 515-20.
22. 22. Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better O, Winaver J. Differential regulation of renal regional blood flow by endothelin-1. Am. J. Physiol. 1996; 271: F1166-72.
23. 23. Qiu C, Engels K, Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J. Am. Soc. Nephrol. 1995; 6: 1476-81.
24. 24. Qiu C, Samsell L, Baylis C. Actions of endogenous endothelin on glomerular hemodynamics in the rat. Am. J. Physiol. 1995; 269: R469-73.
25. B receptors increases glomerular cGMP via an L-arginine-dependent pathway. Am. J. Physiol. 1992; 263: F1020-5.
26. 26. Tack I, Marin Castano E, Pecher C et al. Endothelin increases NO-dependent cGMP production in isolated glomeruli but not in mesangial cells. Am. J. Physiol. 1997; 272: F31-9.
27. 27. Gellai M. Physiological role of endothelin in cardiovascular and renal hemodynamics. Studies in animals. Curr. Opin. Nephrol. Hypertens. 1997; 6: 64-8.
28. 28. Webb D. Physiological role of the endothelin system in human cardiovascular and renal haemodynamics. Curr. Curr. Opin. Nephrol. Hypertens. 1997; 6: 69-73.
29. 29. Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am. J. Physiol. 1993; 264: F212-15.
30. 30. Zatz R, De Nucci G. Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am. J. Physiol. 1991; 261: F360-3.
31. 31. Shultz PJ, Schorer AE, Raij L. Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am. J. Physiol. 1990; 258: F162-7.
32. 32. Filep J. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension 1997; 30: 122-8.
33. 33. Richard V, Hogie M, Clozel M, Loffler B-M, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995; 91: 771-5.
34. B receptor an nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 1997; 30: 51 204-9.
35. 35. Thompson A, Valeri CR, Lieberthal W. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am. J. Physiol. 1995; 269: H743-8.
36. 36. Qiu C, Samsell L, Baylis C. Endothelin (ET) and angiotensin II (AIT) modulate glomerular hemodynamic responses to acute NO blockade (NOB). J. Am. Soc. Nephrol. 1995; 6: 668 (Abstract).
37. 37. Filep JG, Foldes-Filep E, Rousseau A, Sirois P, Fournier A. Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat. Br. J. Pharmacol. 1993; 110: 1213-21.
38. 38. Madeddu P, Anania V, Parpaglia P et al. Endothelin-1 induced renal vasoconstriction is blunted by enalaprilat and enhanced by EDRF antagonist in awake normotensive rats. Clin. Invest. Med. 1991; 14: 6600-6.
39. 39. Ahlborg G, Lundberg J. Nitric oxide-endothelin-1 interaction in humans. J. Appl. Physiol. 1997; 82: 51 593-600.
40. 40. Fitzgerald S, Evans R, Christy I, Anderson W. Nitric oxide synthase blockade and renal vascular responses to norepinephrine and endothelin-1 in conscious dogs. J. Cardiovasc. Pharmacol. 1995; 25: 979-85.
41. 41. Lerman A, Sandok EK, Hildebrand FL, Burnett JC. Inhibition of endothelium derived relaxing factor enhances endothelin mediated vasoconstriction. Circulation 1992; 85: 1894-8.
42. 42. Chou SY, Porush JG. Renal actions of endothelin 1 and endothelin 3: Interactions with the prostaglandin system and nitric oxide. Am. J. Kidney Dis. 1995; 26: 116-23.
43. 43. Matsuo G, Matsumura Y, Tadano K, Hashimoto T, Morimoto S. Effects of sarafotoxin S6c on renal haemodynamics and urine formation in anaesthetized dogs. Clin. Exp. Pharmacol. Physiol. 1997; 24: 487-91.
44. 44. Hirata Y, Matsuoka H, Kimura K et al. Role of endothelium derived relaxing factor in endothelin induced renal vasoconstriction. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 7): S169-71.
45. 45. Ito S, Juncos LA, Nushiro N, Johnson CS, Carretero OA. Endothelium derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension 1991; 17: 1052-6.
46. 46. Edwards RM, Trizna W. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors. J. Am. Soc. Nephrol. 1993; 4: 1127-32.
47. 47. Ito S, Arima S, Ren YL, Juncos LA, Carretero OA. Endothelium derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J. Clin. Invest. 1993; 91: 2012-19.
48. 48. Bloom IT, Bentley FR, Spain GA, Garrison RN. An experimental study of altered nitric oxide metabolism as a mechanism of cyclosporin-induced renal vasoconstriction. Br. J. Surg. 1995; 82: 195-8.
49. 49. Ohishi K, Carmines PK, Inscho EW, Navar LG. EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am. J. Physiol. 1992; 263: F900-6.
50. 50. Baylis C, Deen WM, Myers BD, Brenner BM. Effects of some vasodilator drugs on transcapillary fluid exchange in renal cortex. Am. J. Physiol. 1976; 230: 1148-58.
51. 51. Arima S, Ren Y, Juncos JA, Ito S. Platelet activating factor dilates efferent arterioles through glomerulus derived nitric oxide. J. Am. Soc. Nephrol. 1996; 7: 90-6.
52. 52. Navar LG. Renal autoregulation: Perspectives from whole kidney and single nephron studies. Am. J. Physiol. 1978; 234: F357-70.
53. 53. van Heugten HA, Eskildsen-Helmond YE, de Jonge HW, Bezstarosti K, Lamers JM. Phosphoinositide-generated messengers in cardiac signal transduction. Mol. Cell Biochem. 1996; 157: 5-14.
54. 54. Rajagopalan S, Laursen JB, Borthayre A et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997; 30: 29-34.
55. 55. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998; 31: 10-14.
56. 56. Baylis C, Masilamani S, Losonczy G, Samsell L, Harton P, Engels K. Blood pressure (BP) and renal vasoconstrictor responses to acute blockade of nitric oxide: Persistence of renal vasoconstriction despite normalization of BP with either verapamil or sodium nitroprusside. J. Pharmacol. Exp. Ther. 1995; 274: 1135-41.
57. 57. Zhang XZ, Baylis C. The renal vascular resistance (RVR) remembers a transient increase in renal perfusion pressure (RPP) due to acute systemic NOS inhibition (NOSI). J. Am. Soc. Nephrol. 1997; 8: 356A.
58. 58. Baylis C. The exaggerated prolonged renal vasoconstriction during acute systemic NOS inhibition (NOSI) is due to endothelin (ET). J. Am. Soc. Nephrol. 1998; 9: 334A. (Abstract).
59. 59. Rabelink TJ, Kaasjager KAH, Stroes ESG, Koomans HA. Endothelin in renal pathophysiology. From experimental to therapeutic application. Kidney Int. 1996; 50: 1827-33.